Fox Run Management L.L.C. Makes New Investment in Exelixis, Inc. $EXEL

Fox Run Management L.L.C. purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,291 shares of the biotechnology company’s stock, valued at approximately $321,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Truist Financial Corp increased its position in Exelixis by 1.1% during the 2nd quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company’s stock worth $983,000 after purchasing an additional 250 shares in the last quarter. Frank Rimerman Advisors LLC boosted its stake in shares of Exelixis by 4.7% during the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares during the last quarter. Rathbones Group PLC grew its holdings in shares of Exelixis by 5.3% during the first quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock worth $253,000 after buying an additional 347 shares in the last quarter. Larson Financial Group LLC raised its position in shares of Exelixis by 9.2% in the first quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 367 shares during the last quarter. Finally, Plato Investment Management Ltd raised its position in shares of Exelixis by 6.5% in the second quarter. Plato Investment Management Ltd now owns 6,174 shares of the biotechnology company’s stock valued at $271,000 after buying an additional 377 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research report on Wednesday, October 8th. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. Royal Bank Of Canada restated a “sector perform” rating and set a $45.00 price objective on shares of Exelixis in a report on Tuesday, October 21st. JMP Securities restated a “market outperform” rating and issued a $50.00 price target on shares of Exelixis in a report on Tuesday, July 29th. Finally, Barclays upped their price objective on Exelixis from $40.00 to $41.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.45.

Exelixis Stock Up 1.4%

Shares of NASDAQ EXEL opened at $43.59 on Thursday. The firm’s 50-day moving average price is $39.30 and its two-hundred day moving average price is $40.49. Exelixis, Inc. has a 52-week low of $31.90 and a 52-week high of $49.62. The stock has a market capitalization of $11.69 billion, a P/E ratio of 20.96, a P/E/G ratio of 0.79 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $597.76 million for the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.